awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36881812-FB0A9301-5866-4FE4-B33E-79888CF62C67
Q36881812-FB0A9301-5866-4FE4-B33E-79888CF62C67
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36881812-FB0A9301-5866-4FE4-B33E-79888CF62C67
Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy.
P2860
Q36881812-FB0A9301-5866-4FE4-B33E-79888CF62C67
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36881812-FB0A9301-5866-4FE4-B33E-79888CF62C67
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c9a345bebdc1e29a58ad797f1f34e42340fdb01f
P2860
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.